PART
I
Overview
Since
2008, we have been focused exclusively on efforts to develop a business centered around the commercial manufacturing of highly
pure lithium metal, a raw material for use in lightweight, high energy density batteries, in an environmentally friendly manner.
Additionally, we have broadened our focus to include lithium products and processes derived from our core technology. This includes
battery components such as protected anodes and compounds of lithium, among other things.
Lithium
is the lightest metal with the highest electrochemical potential, making it a clear choice for batteries. There is a substantial
existing market for lithium metal in primary (non-rechargeable) batteries, and rechargeable batteries, including many future opportunities
which exist for next-generation batteries under development.
We
have no revenues and our business is in the development stage. Our operations primarily include activities related to developing
our technology and maintaining our public company status.
During
the year ended December 31, 2018, we commenced research and development efforts at our Yonkers lab facility. We also continued
efforts at research universities and a national research lab for additional work related to development and scale-up of our processes.
Our
Technology
Based
on results to date, including what we believe to be multiple analyses of the process from outside laboratories, we believe that
our proprietary technology offers a number of advantages over lithium production methods currently in use. We also believe based
on results to date that the resulting products have a number of advantages over other lithium products produced via the traditional
ingot method. Traditionally, industrial production of lithium metal involved the electrolysis of molten salts at temperatures
at and above 400° Celsius (752° Fahrenheit). Maintaining these salts at high heat levels adds meaningful production costs
to the process, including the production of chlorine gas as a byproduct.
Our
proprietary technology allows for processing lithium at room temperature of 30° Celsius and allows for the use of lithium
carbonate as a primary feed stock. We believe the advantages of our process and products include:
|
●
|
lower
process temperatures and high electrical efficiency, leading to lower manufacturing costs;
|
|
|
|
|
●
|
reduced
environmental risks, containment costs and regulatory concerns resulting in the elimination of chlorine gas from the production
process;
|
|
|
|
|
●
|
feedstock
flexibility through the use of various grades of lithium carbonate as the feed stock, and reduced non-core hazardous by-products
typically produced when processing halide salts of lithium;
|
|
|
|
|
●
|
electrolytic
deposition of highly pure lithium on a myriad of different substrates in custom form factors with custom protective conductive
coatings;
|
|
|
|
|
●
|
reduced
presence of trace metals or undesired substances in the final products.
|
We
intend to continue developing the intellectual property associated with our core technology; broaden our patent portfolio and
scale up our production of various products.
Starting
in 2012, we devoted our resources internally to developing a technology to manufacture lithium metal, from the lab bench to the
manufacturing floor. We are still in the development stages, but we believe this process and resulting products may be commercially
viable and we are taking preliminary steps toward scaling-up our manufacturing design while we continue to optimize development
efforts.
We
have filed a number of patent applications based on our proprietary room temperature, flexible and energy efficient process. This
proprietary process uses lithium carbonate as a feedstock and does not produce chlorine gas as a by-product. These patent applications
include:
|
●
|
U.S.
Patent Application No. 14/328,613, Filed July 10, 2014 - Producing Lithium
|
|
|
|
|
●
|
PCT
Application No. PCT/US2015/039768, Filed July 9, 2015 - Producing Lithium. The following national phase applications have
been filed from this PCT patent application:
|
|
○
|
Australian
Patent Application No. 2015287769, Filed January 6, 2017
|
|
|
|
|
○
|
Canadian
Patent Application No. 2954639, Filed January 9, 2017
|
|
|
|
|
○
|
Chinese
Patent Application No. 201580037710.4, Filed January 10, 2017
|
|
|
|
|
○
|
European
Patent Application No. 15819217.9, Filed January 23, 2017
|
|
|
|
|
○
|
Japan
Patent Application No.2017-522453, Filed January 6, 2017
|
|
|
|
|
○
|
Korean
Patent Application No. 10-2017-7003400, Filed February 7, 2017
|
|
|
|
|
○
|
Hong
Kong Patent Application No. 17110292.5, Filed October 12, 2017
|
|
●
|
PCT
Application No. PCT/US2016/064328, Filed December 1, 2016 - Method for Producing a Lithium Film
|
|
|
|
|
●
|
PCT
Application No. PCT/US2016/033445, Filed May 20, 2016 - High Purity Lithium and Associated Products and Processes
|
|
|
|
|
●
|
U.S.
Patent Application No. 15/160,013, Filed May 20, 2016- High Purity Lithium and Associated Produces and Processes. The following
national phase applications have been filed from this PCT patent application:
|
|
○
|
Australian
Patent Application No. 2016270313, Filed November 24, 2017
|
|
|
|
|
○
|
Canadian
Patent Application No. 2987740, Filed November 22, 2017
|
|
|
|
|
○
|
Chinese
Patent Application No. 01680031890, Filed November 22, 2017
|
|
|
|
|
○
|
European
Patent Application No. 16803991.5, Filed October 24, 2017
|
|
|
|
|
○
|
Japan
Patent Application No. 2018-513724, Filed November 23, 2017
|
|
|
|
|
○
|
Korean
Patent Application No. 10-2017-7037256, Filed November 22, 2017
|
|
|
|
|
○
|
Indian
Patent Application No. 201717042986, Filed November 22, 2017
|
|
|
|
|
○
|
U.S.
Continuation-In-Part Application No. 15/821,275, Filed November 22, 2017
|
The
PCT patent application, Method for Producing a Lithium Film, includes certain intellectual property that has been jointly developed
in partnership with the City University of New York and has been exclusively licensed to alpha-En.
Our
patent applications encompass a broad portfolio of products and processes derived from our core lithium production technology,
ranging from processes to produce compounds of lithium, battery components and battery technology using our high purity lithium
metal products.
In
November 2018 the U.S. Patent and Trademark Office issued a Notice of Allowance for our Patent Application No. 15/160,013 - High
Purity Lithium and Associated Produces and Processes.
Prior
to 2012 we also pursued a strategy of in-licensing. On February 25, 2009, we were granted an exclusive, worldwide, transferable,
perpetual license to use certain proprietary technology for the processing of lithium for use in batteries and other fields. Commencing
in October 2010, working through a third party, we conducted a series of tests to determine if the process worked and, based on
the results, initially believed that the process produced lithium, however it did not prove to be commercially feasible and research
and development efforts involving this license were abandoned. In exchange for the license, we had certain financial, share issuance
and royalty obligations if certain sale thresholds were met. However, since such thresholds were not met and the technology was
not used, we negotiated an amendment and release related to this license, which became effective in January of 2017.
From
2013 to the present, our operations primarily included activities related to development of our technology and maintaining our
public company status. We have had no revenues in any of these years as our business was and continues to be in the development
stage.
Currently,
we are attempting to further develop the intellectual property associated with our core technology; broaden our patent portfolio;
scale up our production of various products; and begin generating revenue; however, our cash position may not be sufficient to
support our daily operations. While we believe in the viability of our strategy to further develop our technology and generate
revenue and in our ability to raise additional funds by way of a public or private offering, there can be no assurance that we
will succeed. Our ability to continue as a going concern is dependent upon our ability to raise additional funds by way of a public
or private offering and to further develop our technology and generate sufficient revenue.
Competition
The
market for the lithium and related products is highly competitive. There are numerous competitors in the industry, most of which
have substantially more financial resources, greater manufacturing capacity, research and development capability, and marketing
resources than us.
Regulation
Lithium
metal is classified as a hazardous material, and some of the chemicals we use are also classified as hazardous materials. We are
required by law to comply with environmental regulations pertaining to the use, handling, and disposal of lithium metal as well
as the other chemicals. Lithium battery chemistries react adversely with water and water vapor, and under certain circumstances
can cause fires. As such, lithium based batteries are subject to government regulation in various jurisdictions. We ship out small
quantities of lithium metal samples and we conform to the regulatory requirements associated with such transportation.
Employees
As
of December 31, 2018, we have eight full-time employees and no part-time employees. We also engage five consultants who work on
a part-time basis. None of these employees are covered by a collective bargaining agreement, and we believe our relationship with
our employees is in good standing. We also occasionally engage consultants on an as-needed basis to supplement existing
staff. We also rely on outsourced research and development relationships with a number of academic research institutions as part
of our process for developing and validating our core technology.
An
investment in our Company is highly speculative in nature and involves an extremely high degree of risk. You should carefully
consider the following material risks, together with the other information contained in this report, before you decide to buy
our common stock. If any of the following risks actually occur, our business, results of operations and financial condition would
likely suffer. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your
investment.
We
have a limited operating history and no revenue; we have accumulated deficits; we are only in an initial commercialization stage
with technology that is unproven on a large-scale commercial basis; and there is a going concern explanatory paragraph in our
independent registered public accounting firm’s report.
Our
company reduced daily operations in late 2005 and essentially ceased daily operations in May 2006. Through January 2009, we were
substantially inactive. In February 2009, we entered into a technology license agreement for a process to produce lithium metal.
We do not utilize this technology for any purpose because it did not produce the intended result. From 2012 to the present, we
have devoted our resources to develop a different lithium manufacturing technology from that initially undertaken in 2009. Because
we are still in the developmental stage, there is a limited operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited
to, risks of unforeseen capital requirements, failure of market acceptance, failure to establish business relationships and competitive
disadvantages as against larger and more established companies.
The
report of our independent registered public accounting firm with respect to our consolidated financial statements included in
this report includes a “going concern” explanatory paragraph. As reflected in the consolidated financial statements,
we had an accumulated deficit of approximately $25.6 million and $20.3 million at December 31, 2018 and 2017, a net loss of approximately
$5.5 million and $6.9 million, and approximately $3.6 million and $2.0 million net cash used in operating activities for the years
ended December 31, 2018 and 2017, respectively. These factors raise substantial doubt about the Company’s ability to continue
as a going concern.
We
have generated no revenues from our lithium technology and will not generate any meaningful revenues until after we have successfully
commercialized our new proprietary technology to manufacture high purity lithium metal and associated products, of which no assurance
can be given. We have continued to incur significant losses and anticipate that we may continue to incur significant losses in
2019 and beyond. There can be no assurance as to whether or when we will generate meaningful revenues or achieve profitable operations.
Our
lithium production technology has never been utilized on a large-scale basis, and there can be no assurance that this technology
will perform successfully on a large-scale commercial basis or that it will be profitable for us. All of the tests conducted to
date by us with respect to our new process and technology have been conducted in the laboratory on small scale only, and there
can be no assurance that the same or similar results could be obtained on a large-scale commercial basis. Additionally, our ability
to operate our business successfully will depend on a variety of factors, many of which are outside our control, including competition,
cost and availability of strategic components, changes in governmental initiatives and requirements, changes in regulatory requirements,
and the costs associated with commencing pilot manufacturing.
We
have identified material weaknesses in our internal control over financial reporting. If we fail to develop or maintain an effective
system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, current
and potential stockholders could lose confidence in our financial reporting, which could harm our business and the trading price
of our stock.
During
the preparation of our consolidated financial statements for the year ended December 31, 2018, we and our independent registered
public accounting firm identified deficiencies in our internal control over financial reporting, as defined in the standards established
by the Public Company Accounting Oversight Board. Management determined the control deficiencies constitute material weaknesses
in our internal control over financial reporting.
The
existence of a material weakness could result in errors in our consolidated financial statements, cause us to fail to meet our
reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in the
trading price of our stock.
There
remains uncertainty of any market acceptance of our technology to manufacture lithium metal.
Many
prospective users of lithium metal have already committed substantial resources to other existing forms of battery technology.
Our growth and future financial performance will depend on our ability to demonstrate to prospective users the technical and economic
advantages of our technology to manufacture lithium metal over alternative technologies. There can be no assurance that we will
be successful in this effort. Furthermore, it is possible that competing technologies may be perceived to have, or may actually
have, certain advantages over our technology or lithium metal in general for certain industries or applications.
We
have a need for additional financing in the foreseeable future.
During
the past three years, financing for all of our activities has been provided in the form of direct equity investments, private
placements and advances from our officers and directors. Our future capital requirements could vary significantly and will depend
on certain factors, many of which are not within our control. These include the ongoing development and testing of our technology
to manufacture lithium metal, the nature and timing of prospective commercial projects and permits required and the availability
of financing. In the battery market, we may not be able to enter into favorable business collaborations and might thus be required
to seek project contracts for our own account. If such efforts were successful, we would be required to make significant expenditures
on personnel and capital equipment which would require significant financing. In addition, our lack of operational experience
and limited capital resources could make it difficult, if not highly unlikely, to successfully secure major projects. In such
event, our business development could be limited to smaller commercial projects with significantly lower potential for profit.
In
addition, the expansion of our business will require the commitment of significant capital resources toward the hiring of technical
and operational support personnel and the development of a manufacturing and testing facility. In the event we are presented with
one or more significant projects, individually or in conjunction with collaborative working partners, we may require additional
capital to take advantage of such opportunities. There can be no assurance that such financing will be available or, if available,
that it will be on favorable terms. If adequate financing is not available, we may be required to delay, scale back or eliminate
certain of our research and development programs, to relinquish rights to certain of our technologies, or to license third parties
to commercialize technologies that we would otherwise seek to develop ourselves. To the extent we raise additional capital by
issuing equity securities, stockholders will be diluted.
We
may not be able to obtain or enforce patent rights or other intellectual property rights that cover our product candidates and
technologies that are of sufficient breadth to prevent third parties from competing against us.
Our
success with respect to our product candidates and technologies will depend in part upon our ability to obtain and maintain patent
protection in both the United States and other countries, to preserve our trade secrets and to prevent third parties from infringing
upon our proprietary rights. Our ability to protect any of our product candidates from unauthorized or infringing use by third
parties depends in substantial part upon our ability to obtain and maintain valid and enforceable patents.
Our
patent portfolio currently is made up entirely of pending patent applications, with the exception of our Patent Application No.
15/160,013 - High Purity Lithium and Associated Produces and Processes, which received a Notice of Allowance from the U.S. Patent
and Trademark Office in November 2018. Although we received this Notice of Allowance, the patent for our Patent Application No.
15/160,013 has not yet issued. Any patents that we do obtain may be narrow in scope and thus easily circumvented by competitors.
Further, in countries where we do not have granted patents, third parties may be able to make, use or sell products identical
to or substantially similar to, our product candidates. The patent application process is expensive and time-consuming, and we
may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner. It is possible that defects of form in the preparation or filing of our patent applications may exist, or may arise in
the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If there are
material defects in the form or preparation of our patent applications, such applications may be invalid and unenforceable. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability
to prevent competition from third parties, which may have an adverse impact on our business, financial condition and operating
results.
We
face competition and technical alternatives in the overall battery market.
We
anticipate that our primary market will be for lithium metal batteries. We have had limited experience in manufacturing and marketing
our technology and have not previously had any employees or personnel whose primary responsibilities consisted of these functions.
Other participants include several large domestic and international companies and numerous small companies, many of whom have
substantially greater financial and other resources and more manufacturing, marketing and sales experience than we do. In addition,
as lithium metal technology evolves, there exists the possibility that our technology may be rendered obsolete by one or more
competing technologies. Any one or more of our competitors, or one or more other enterprises not presently known to us, may develop
technologies which are superior to our technology. To the extent that our competitors are able to offer more cost-effective alternatives,
our ability to compete could be materially and adversely affected.
There
can be no assurance that we will enter into collaborative agreements or projects utilizing our technology in the future.
We
propose to pursue opportunities in the battery market through collaborative joint working arrangements with companies that have
a significant presence in well-established industries or markets, and that can introduce our technology to industry participants.
However, neither we nor any of our prospective collaborative joint working partners have secured any project contracts. There
can be no assurance that we will enter into any definitive joint project arrangements with our prospective working partners or
others, or that any such definitive arrangements will be on terms and conditions that will enable us to generate profits. Furthermore,
even if we are successful in obtaining one or more project awards, such projects may be curtailed or eliminated, or other problems
may arise, which could materially adversely affect our business, financial condition and results of operations.
We
depend on our senior executive officers and other personnel to run our business.
We
are dependent on the efforts of our senior executive officers, particularly Jerome I. Feldman, our Executive Chairman and until
March 1, 2017, our Chief Financial Officer, Sam Pitroda, our Chief Executive Officer since November 1, 2017, Nathan J. Wasserman,
our Chief Financial Officer since March 1, 2017, and Vinder Sokhi, our Chief Operating Officer since May 31, 2018. We do not have
key-man life insurance policies on the lives of Messrs. Feldman, Pitroda, Wasserman or Sokhi to compensate us for the loss of
such individuals. The loss of the services of any one or more of such persons may have a material adverse effect on our company.
Our
future success will depend in large part upon our ability to attract and retain skilled scientific, management, operational and
marketing personnel. We face competition for hiring such personnel from other companies, including companies that have greater
resources. There can be no assurance that we will be successful in attracting and retaining such personnel.
We
rely primarily on internal research and development efforts to bring our products to commercialization, and we may fail to develop
our technology on a timely basis or at all.
During
the year ended December 31, 2018 we began to scale up our internal research and development efforts at our Yonkers lab, and we
intend to rely primarily on internal research and development efforts for the foreseeable future. Research and development activities
are inherently uncertain and the results of our in-house research and development may not be successful. We believe that our future
success will depend in large part upon our ability to further refine our technology and scale up our technology through in-house
research efforts. If we are unable to do so, our business, operating results, financial condition and reputation could be materially
harmed.
Because
we have entered into a substantial financial commitment for leased office and laboratory space, funds may be diverted from other
important matters in the development of our business and could negatively impact our financial position.
On
March 22, 2016, the Company entered into a lease for office and laboratory space located in Yonkers, New York, consisting of approximately
8,000 square feet. The lease has a term of 87 months and the annual rent for the first year of the lease is approximately $208,000,
increasing by 1.5% in each subsequent year. In the event of a termination of the lease following a default by the Company, the
Company will be obligated to pay the sum of the rent payable for the remainder of the lease term. This represents a substantial
financial commitment for us. Money that could be spent elsewhere will be needed to fulfill the lease commitment, which may divert
funds away from other important matters in the development of our business and could negatively impact our financial position.
We
will need to comply with government regulations, which can be costly and time-consuming.
We
may be required to comply with a number of federal, state and local laws and regulations in the areas of safety, health and environmental
controls, including without limitation, the Resource Conservation and Recovery Act (RCRA), as amended, and the Occupational Safety
and Health Act of 1970 (OSHA), which may require us to obtain permits or approvals to utilize, handle, and dispose of lithium
metal and/or other chemicals. Furthermore, particularly in the battery market, we may be required to conduct performance and operating
studies to assure government agencies that our technology does not pose environmental or product safety risks. Changes in environmental
or safety regulations, the discovery of conditions not currently known to us, or other developments could result in the imposition
of additional or different environmental compliance obligations or expenditure for capital improvements. We do not believe at
this time that financial obligations incurred in connection with environmental regulatory compliance will have a material adverse
effect on the company’s financial condition, competitive position or results of operations. Our belief is based on the company’s
understanding of the underlying facts giving rise to its environmental regulatory obligations.
We
are controlled by a small number of “insider” stockholders.
Our
directors and executive officers currently beneficially own approximately 54.8 % of our outstanding common stock. Accordingly,
through their collective ownership of our outstanding common stock, if they act together, they will be able to control the voting
of our shares at all meetings of stockholders and, because the common stock does not have cumulative voting rights, will be able
to determine the outcome of the election of all of our directors and determine corporate and stockholder action on other matters.
We
have no plans to pay dividends.
We
have never paid any dividends on our common stock and have no plans to pay dividends on our common stock in the foreseeable future.
The payment of dividends on our common stock is within the discretion of our Board of Directors, subject to our certificate of
incorporation. We intend to retain any earnings for use in our operations and any expansion of our business. Payment of dividends
in the future will depend on our future earnings, future capital needs and our operating and financial condition, among other
factors.
It
is likely that our common stock price will be volatile.
The
stock market has from time to time experienced significant price and volume fluctuations that may be unrelated to the operating
performances of specific companies. Announcements of new technologies and changing policies and regulations of the federal government
and state governments and other external factors, as well as potential fluctuations in our financial results, may have a significant
impact on the price of our stock.
Our
charter contains some anti-takeover provisions that may inhibit a takeover.
The
provisions in our certificate of incorporation relating to a classified Board of Directors and delegation to the Board of Directors
of rights to determine the terms of preferred stock may have the effect not only of discouraging attempts by others to buy us,
but also of making it more difficult or impossible for existing stockholders to make management changes. A classified board, which
is made up of directors elected for staggered terms, while promoting stability in board membership and management, also moderates
the pace of any change in control of our Board of Directors by extending the time required to elect a majority, effectively requiring
action in at least two annual meetings. The ability of our Board of Directors to determine the terms of preferred stock, while
providing flexibility in connection with possible business purchases and other corporate purposes, could make it more difficult
for a third party to secure a majority of our outstanding common stock. Additionally, we are subject to the anti-takeover provisions
of Section 203 of the Delaware General Corporation Law, which prohibits us from engaging in a “business combination”
with an “interested stockholder” for a period of three years after the date of the transaction in which the person
became an interested stockholder, unless the business combination is approved in a prescribed manner. Section 203 could have the
effect of delaying or preventing a change of control.
ITEM
1B.
|
Unresolved
Staff Comments
|
None.
On
March 22, 2016, we entered into a lease (the “Lease”) with Hudson View Building #3, LLC (“the “Landlord”),
for office and laboratory space located in Yonkers, New York (the “Leased Premise”). The Leased Premise consists of
approximately 8,000 square feet. The Lease has a term of 87 months from the lease commencement date, which is the date upon which
the Landlord has substantially completed certain interior leasehold improvements to the Leased Premise. The annual rent of the
first year of the lease is approximately $208,000, increasing by 1.5% on each anniversary of the lease commencement date. In the
event of a termination of the lease following a default by us, we will be obligated to pay the sum of the rent payable for the
remainder of the lease term. We moved into the office on May 30, 2017. We began paying the monthly rent during the quarter ended
September 30, 2017. On March 31, 2018, we entered into a lease amendment agreement with the Landlord, which resulted in abatement
of rent for the period from October 2017 through March 2018, and the expiration date of the Lease was extended to March 31, 2025.
In
connection with this lease, we obtained an Irrevocable Standby Letter of Credit (the “Letter of Credit”) from Chase
Bank for a sum not exceeding $150,000. We have deposited this amount with Chase Bank as collateral for the Letter of Credit and
recorded the amount as restricted cash and long-term deposits in the balance sheets. During the year ended December 31, 2017,
$100,000 restricted cash was released to us.
As
of December 31, 2018, contractual minimal lease payments are as follows (in thousands):
2019
|
|
$
|
212
|
|
2020
|
|
|
215
|
|
2021
|
|
|
219
|
|
2022
|
|
|
222
|
|
2023
|
|
|
225
|
|
Thereafter
|
|
|
286
|
|
Total
|
|
$
|
1,379
|
|
ITEM
3.
|
Legal
Proceedings
|
In
December 2018 the Company received a letter from an attorney representing a former employee and claiming damages for wrongful
termination. The Company is evaluating the merits of these claims.
ITEM
4.
|
Mine
Safety Disclosures
|
Not
applicable.
PART
III
ITEM
10.
|
Directors,
Executive Officers and Corporate Governance
|
The
following table shows the positions held by our Board of Directors and executive officers, and their ages, as of the date of this
Form 10-K:
Name
|
|
Age
|
|
Position
|
Jerome
I. Feldman
|
|
90
|
|
Executive
Chairman of the Board and Treasurer
|
Sam
Pitroda
|
|
77
|
|
Chief
Executive Officer and Director
|
Nathan
J. Wasserman
|
|
71
|
|
Chief
Financial Officer
|
George
McKeegan
|
|
71
|
|
Vice
President, Secretary, General Counsel and Director
|
Steven
M. Payne
|
|
65
|
|
Director
|
Page
Feldman
|
|
52
|
|
Director
|
Vinder
Sokhi
|
|
47
|
|
Director
and Chief Operating Officer
|
Jim
Kilman
|
|
57
|
|
Director
|
The
background of each of our directors and executive officers are as follows:
Jerome
I. Feldman
has been our Executive Chairman of the Board since December 2008 (he previously was the Vice Chairman) and our
Chief Executive Officer from March 2011 to October 2015, and has been a member of our Board of Directors and our Chief Financial
Officer and Treasurer since September 2006. In October 2015, he resigned as our Chief Executive Officer. Mr. Feldman founded GP
Strategies Corp., which provides training, engineering and consulting services to the automotive, steel, energy and government
industries, in 1959 and served as its Chief Executive Officer from 1959 until April 2005, Chairman of the Board from 1999 until
April 2005, and President from 1959 until 2001. He has been Chairman of the Board of Five Star Products, Inc., a paint and hardware
distributor, from 1994 until June 2007, a director of GSE Systems, Inc., a leading global provider of real-time simulation and
training solution to the power, process, manufacturing and government sectors, from 1994 until August 2015, Chairman of the Board
of GSE Systems from 1997 until August 2015, and Chairman of the Board and Chief Executive Officer of National Patent Development
Corp. (“NPDC”), which was devoted to searching out new inventions and assisting major corporations in licensing their
technologies, from 2004 until June 2007. He was a director of Valera Pharmaceuticals, a specialty pharmaceutical company, from
January 2005 until April 2007. Mr. Feldman was also Chairman of the New England Colleges Fund and a Trustee of Northern Westchester
Hospital Foundation. He has a B.A. degree from Indiana University and an LLB degree from New York University. During his tenure
with the NPDC, they developed the soft contact lense, founded U.S. surgical and a number of other technical developments.
As
the Executive Chairman, Mr. Feldman leads the board and guides our company. Mr. Feldman brings extensive industry knowledge to
our company and a deep background in technology growth companies.
Sam
Pitroda
became our Chief Executive Officer on November 1, 2017, and has been a member of our Board of Directors since June
2018. Mr. Pitroda is an information technology and telecommunications inventor and entrepreneur. He was the founder and former
Chief Executive Officer of C-Sam, Inc. a provider of mobile wallets and other on-device software, which was founded in 1998 and
purchased in 2014 by MasterCard. Earlier in his career Mr. Pitroda also founded a number of other telecommunications companies
in India and the U.S. Mr. Pitroda also served as advisor to Prime Minister Indira Gandhi of India on Public Information Infrastructure
and Innovation and as a Cabinet Minister under Rajiv Gandhi. Mr. Pitroda has an MS and BS in Physics from Maharaja Sayajai Rao
University in India and an M.S. in Electrical Engineering from Illinois Institute of Technology.
Nathan
J. Wasserman
became our Chief Financial Officer on March 1, 2017. Mr. Wasserman is the owner and President of Columbia Enterprises,
Inc., a state-of-the-art digital reprographic firm located in Manhattan, New York. Prior to joining Columbia Enterprises, Mr.
Wasserman was an audit partner and certified public accountant (CPA) at Deloitte & Touche LLP, a multi-national professional
services firm where he worked for 16 years. Mr. Wasserman holds a BBA in accounting from Kent State University. Mr. Wasserman
has maintained his CPA status and is a member of the American Institute of Certified Public Accountants (AICPA) and the New York
State Society of Certified Public Accountants (NYSSCPA).
George
McKeegan
has been our Vice President or Executive Vice President, Secretary and General Counsel, and a member of our Board
of Directors since May 2006. Since 1986, Mr. McKeegan has led Cavanaugh & McKeegan, P.C., a law firm engaged in the general
practice of civil law and specializing in litigation and corporate counseling. Prior to that, he served as Vice President at Citibank,
N.A. and as an Assistant District Attorney with the New York County District Attorney’s Office. He received a B.A. degree
from Fordham College and a J.D. degree from the University of Michigan. Mr. McKeegan’s almost 30 years of working experience
in corporate controls and governance makes him well qualified to be a member of our board.
Steven
M. Payne
has been a member of our Board of Directors since May 2006 and was our President from May 2006 to December 2012.
Since 1976, Mr. Payne has served as President and Chief Executive Officer of Quatro Foods Inc., a food service enterprise. He
is a director and past Board President of Carbondale Main Street, Inc., a local downtown redevelopment corporation, and a director
of the Southern Illinois Entrepreneurship and Business Development Center at Southern Illinois University in Carbondale, Illinois.
Mr. Payne is also President of 13 West LLC, a developer and operator of Mini Storage facilities. He attended Southern Illinois
University. Mr. Payne’s experience in running businesses and advising entrepreneurial ventures makes him well qualified
to be a member of our board.
Page
Feldman
has been a member of our Board of Directors since June 2018. Ms. Feldman is an Emmy nominated TV Executive Producer
and President of Scoutabout Entertainment, a company she founded in 2016. Her career in entertainment has spanned across feature
films, animation, large-scale network TV series, branded content, documentaries, and national commercials. Ms. Feldman worked
at Mark Burnett Productions for 12 years on many of Burnett’s marquee programs including: Rock Star, Contender, and The
Celebrity Apprentice. She was Executive Producer of “The Celebrity Apprentice” for 10 seasons and was responsible
for sales and contracts of the trademark business model of branded integration, brokering over 80 million dollars in sponsorship
deals with dozens of corporations. Simultaneous to her Apprentice commitment Ms. Feldman spent four years producing the boxing
series “The Contender”, hosted by Sugar Ray Leonard. She is currently producing an Amazon series due to air in spring
2020. Ms. Feldman has a B.S. from Kenyon College.
Vinder
Sokhi
has been a member of our Board of Directors since June 2018 and has served as our Chief Operating Officer since May
31, 2018. Mr. Sokhi has more than a decade of experience in investments and global finance in addition to being a seasoned entrepreneur
having started his own software company after college. His key expertise is in calculating valuation of public companies and has
created several models for investment portfolio management. In addition to raising capital for early stage companies such as alpha-En,
Mr. Sokhi also advises a family office, directly overseeing the management of a portfolio valued at over $50 million. Mr. Sokhi
holds a Bachelor of Engineering in Computer Science from DYP College of Engineering, India.
Jim
Kilman
has been a member of our Board of Directors since November 2016. Mr. Kilman is Chief Executive Officer of Scarborough,
NY-based KielStrand Capital, a family office merchant bank that makes and manages investments, provides advisory services and
engages in philanthropic activities. He retired in 2016 as Vice Chairman of Investment Banking at Morgan Stanley, having spent
a total of 32 years in senior investment banking roles, including at Goldman Sachs, ABN AMRO and PaineWebber. Mr. Kilman currently
serves as a Trustee of the MFS Mutual Funds, a Director of Recombinetics Inc., a Senior Advisor of Burford Capital Ltd., a Board
Member of the Hudson Valley Shakespeare Festival and acting Treasurer of the Jacob Burns Film Center. He previously served as
a Director of Modular Space Corporation and of Lebenthal Holdings LLC. Mr. Kilman holds an MA and a BA in Economics from Yale
University.
Our
directors are divided into three classes. At each annual meeting of stockholders, directors are elected to succeed those directors
whose terms expire and are elected for a term of office to expire at the third succeeding annual meeting of stockholders after
their election. Under our bylaws, the number of directors constituting the entire Board of Directors shall be fixed, from time
to time, by the directors then in office, who may decrease or increase the number of directors by majority action without soliciting
stockholder approval. We do not currently pay compensation to directors for service in that capacity.
Committees
of the Board
We
have established an audit committee. We have not established a compensation committee or nominations and governance committee,
and we are not required to do so since our shares are not listed on a national securities exchange.
None
of our directors or executive officers or their respective associates or affiliates is indebted to us.
Family
Relationships
Page
Feldman, one of our Directors, is the daughter of Jerome Feldman, our Executive Chairman of the Board and Treasurer.
Legal
Proceedings
No
officer, director, persons nominated for such positions, promoter or significant employee has been involved in the last ten years
in any of the following:
|
●
|
Any
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time;
|
|
|
|
|
●
|
Any
conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other
minor offenses);
|
|
|
|
|
●
|
Being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring suspending or otherwise limiting his involvement in any type of business, securities
or banking activities;
|
|
|
|
|
●
|
Being
found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission
to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated;
|
|
|
|
|
●
|
Being
the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, relating to an alleged violation of (i) any Federal or state securities or commodities law
or regulation, (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited
to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
cease-and-desist order, or removal or prohibition order or (iii) any law or regulation prohibiting mail or wire fraud or fraud
in connection with any business entity; and
|
|
|
|
|
●
|
Being
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
organization, any registered entity, or any equivalent exchange, association, entity or organization that has disciplinary
authority over its members or persons associated with a member.
|
Code
of Ethics
In
December 2007, we adopted a Code of Ethics and Business Conduct that applies to all of our executive officers, directors and employees,
which was updated in March 2015. The Code of Ethics and Business Conduct codifies the business and ethical principles that govern
all aspects of our business. Our Code of Ethics and Business Conduct is available without charge to any stockholder who makes
a written request for a copy. Our Code of Ethics and Business Conduct is available on our website at http://alpha-encorp.com.
If we make any amendments to or grant any waivers from our Code of Ethics, we will post such information on our website.
Section
16(a) Beneficial Ownership Reporting Compliance
Rules
adopted by the SEC under Section 16(a) of the Exchange Act, require our officers and directors, and persons who own more than
ten percent of the issued and outstanding shares of our equity securities, to file reports of their ownership, and changes in
ownership, of such securities with the SEC on Forms 3, 4 or 5, as appropriate. Such persons are required by the regulations of
the SEC to furnish us with copies of all forms they file pursuant to Section 16(a).
We
believe that all of the officers, directors, and owners of more than ten percent of the outstanding shares of our common stock
complied with Section 16(a) of the Exchange Act for the year ended December 31, 2018, except with respect to certain option grants
and with respect to a stock issuance made to a director and stockholder which was made in lieu of repayment of a loan to the company.
ITEM
11.
|
Executive
Compensation
|
Summary
Compensation Table
The
following table sets forth, for the most recent fiscal year and prior fiscal year, all cash compensation paid, distributed or
accrued, including salary and bonus amounts, for services rendered to us by our principal executive officer and two other executive
officers in such year who received or are entitled to receive remuneration in excess of $100,000 during the stated period and
any individuals for whom disclosure would have been made in this table but for the fact that the individual was not serving as
an executive officer at December 31, 2018:
Name
and Principal Position
|
|
Year
|
|
|
Salary
($)
|
|
|
Stock
Awards
($)
|
|
|
Option
Awards
($)
|
|
|
Total
($)
|
|
Jerome
I. Feldman
|
|
2018
|
|
|
$
|
60,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
60,000
|
|
Executive
Chairman, Chief Financial Officer and Treasurer
|
|
2017
|
|
|
$
|
60,000
|
|
|
$
|
-
|
|
|
$
|
1,043,000
|
|
|
$
|
1,103,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sam
Pitroda(1)
|
|
2018
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
7,629,000
|
|
|
$
|
-
|
|
Chief
Executive Officer and Director
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nathan
Wasserman(2)
|
|
2018
|
|
|
$
|
60,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
60,000
|
|
Chief
Financial Officer
|
|
2017
|
|
|
$
|
60,000
|
|
|
$
|
-
|
|
|
$
|
611,000
|
|
|
$
|
671,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
George
McKeegan
|
|
2018
|
|
|
$
|
12,500
|
|
|
$
|
-
|
|
|
$
|
267,000
|
|
|
$
|
279,500
|
|
Vice
President, Secretary and General Counsel
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
241,000
|
|
|
$
|
241,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vinder
Sokhi(3)
|
|
2018
|
|
|
$
|
15,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
15,000
|
|
Director,
Chief Operating Officer
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
(1)
|
Mr.
Pitroda joined our company on November 1, 2017.
|
|
(2)
|
Mr.
Wasserman joined our company on March 1, 2017.
|
|
(3)
|
Mr.
Sokhi joined our company on May 31, 2018.
|
Outstanding
Equity Awards at Fiscal Year-End
The
following tables summarizes equity awards outstanding at December 31, 2018, for each of the executive officers named in the Summary
Compensation Table above:
Outstanding
Equity Awards at December 31, 2018
|
|
Option
Awards
|
|
|
Stock
Awards
|
|
Name
|
|
Number
of Securities Underlying Unexercised Options
(#)
Exercisable
|
|
|
Number
of Securities Underlying Unexercised Options
(#)
Unexercisable
|
|
|
Option
Exercise
Price
($)
|
|
|
Option
Expiration
Date
|
|
|
Number
of Shares or Units of Stock That Have Not Vested
(#)
|
|
|
Market
Value of Shares or Units of Stock That Have Not Vested
($)
|
|
Jerome
I. Feldman
|
|
|
500,000
|
|
|
|
500,000
|
|
|
$
|
1.95
|
|
|
|
7/26/2022
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nathan
Wasserman
|
|
|
300,000
|
|
|
|
200,000
|
|
|
$
|
1.1
|
|
|
|
1/27/2022
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sam
Pitroda
|
|
|
-
|
|
|
|
7,000,000
|
|
|
$
|
2.08
|
|
|
|
5/31/2025
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
George
McKeegan
|
|
|
300,000
|
|
|
|
200,000
|
|
|
|
(1
|
)
|
|
|
(2
|
)
|
|
|
-
|
|
|
|
-
|
|
|
(1)
|
250,000
shares of the option have an exercise price of $1.90 and another 250,000 shares of the option have an exercise price of $1.95.
|
|
(2)
|
250,000
shares of the option will expire on 5/31/2023 and another 250,000 shares of the option will expire on 7/26/2022.
|
Employment
Agreements
On
November 11, 2017, the Company appointed Sam Pitroda to serve as the Company’s new Chief Executive Officer. Since that time,
Mr. Pitroda has served as CEO without an employment agreement. On May 31, 2018, the board of directors approved to grant Mr. Pitroda
an option to purchase 7,000,000 shares of the Company’s common stock at an exercise price of $2.08 per share. The option
expires seven years from the option grant date. The stock subject to the option will vest upon the earlier to occur of (1) the
five-year anniversary of the option grant date or (2) the achievement of certain stock price and volume milestones, which are
as follows:
|
|
|
For
20 consecutive business
|
|
|
Total
option shares that
|
Common
stock price
|
|
|
days,
with average daily
|
|
|
become
vested on satisfaction
|
closes
at or above
|
|
|
volumn
in excess of
|
|
|
of
conditions
|
$
|
3.00
|
|
|
|
20,000
|
|
|
2,000,000
(28.5%)
|
$
|
6.00
|
|
|
|
40,000
|
|
|
4,000,000
(51.7%)
|
$
|
11.00
|
|
|
|
60,000
|
|
|
7,000,000
(100.0%)
|
On
February 23, 2017, the Board of Directors of the Company appointed Nathan Wasserman to become Chief Financial Officer of the Company,
effective as of March 1, 2017. Pursuant to a term sheet dated February 27, 2017, Mr. Wasserman agreed to serve as the Company’s
Chief Financial Officer for an initial term of three years. The Company granted Mr. Wasserman stock options to purchase a total
of 500,000 shares of common stock at an exercise price of $1.10 per share, of which 150,000 vested immediately, 150,000 vested
in his second year of service and 200,000 will vest in his third year of service. Mr. Wasserman receives a salary of $5,000 per
month.
Director
Compensation
Directors
currently receive no cash compensation for serving on our Board of Directors, other than reimbursement of reasonable expenses
for attendance at board meetings. Starting in 2017 our directors began to receive compensation for their services through grants
of stock options to purchase common stock. Decisions for issuing Stock option grants as compensation for service on our Board
of Directors for the year ending December 31, 2018 have not yet been made. The following table sets forth, for the most recent
fiscal year and prior fiscal year, all cash compensation paid, distributed or accrued for services rendered to us:
Name
and Principal Position
|
|
Year
|
|
|
Salary
($)
|
|
|
Stock
Awards
($)
|
|
|
Option
Awards
($)
|
|
|
Total
($)
|
|
Jim
Kilman
|
|
|
2018
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Director
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,043,000
|
|
|
$
|
1,043,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Steven
Payne
|
|
|
2018
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Director
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
522,000
|
|
|
$
|
522,000
|
|
ITEM
12.
|
Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
The
table below sets forth information, as of March 29, 2019, with respect to the beneficial ownership (as defined in Rule
13d-3 of the Exchange Act) of our common stock by each person who is known by the Company to beneficially own more than five percent
of the Company’s Common Stock, each of our directors and our named executive officers, and all of our directors and executive
officers as a group.
The
beneficial ownership of each person was calculated based on 39,044,549 shares of our common stock outstanding as of March 29,
2019 according to the record ownership listings as of that date and the verifications we solicited and received from each director
and executive officer. The SEC has defined “beneficial ownership” to mean more than ownership in the usual sense.
For example, a person has beneficial ownership of a share not only if he owns it in the usual sense, but also if he has the power
to vote, sell or otherwise dispose of the share. Beneficial ownership also includes the number of shares that a person has the
right to acquire within 60 days of March 29, 2019, pursuant to the exercise of options or warrants or the conversion of
notes, debentures or other indebtedness, but excludes stock appreciation rights. Two or more persons might count as beneficial
owners of the same share. Unless otherwise noted, the address of the following persons listed below is c/o alpha-En Corporation,
28 Wells Avenue, 2
nd
Floor, Yonkers, New York, 10701.
Unless
otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to
all shares of common stock beneficially owned by them.
Name
|
|
Position
|
|
Shares
of
Common
Stock
Beneficially
Owned
|
|
|
Percent
of
Common
Stock
Beneficially
Owned
|
|
|
|
|
|
|
|
|
|
|
5%
Stockholder:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael
D. Feldman
|
|
Former
Chairman and Chief Executive Officer
|
|
|
4,029,500
|
(8)
|
|
|
10.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Directors
and Executive Officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerome
I. Feldman
|
|
Executive
Chairman of the Board and Treasurer
|
|
|
10,705,371
|
(1)
|
|
|
27.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Sam
Pitroda
|
|
Chief
Executive Officer and Director
|
|
|
562,525
|
(2)
|
|
|
1.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
George
McKeegan
|
|
Vice
President, Secretary, General Counsel and Director
|
|
|
1,050,000
|
(3)
|
|
|
2.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Nathan
J. Wasserman
|
|
Chief
Financial Officer
|
|
|
520,000
|
(4)
|
|
|
1.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Steven
M. Payne
|
|
Director
|
|
|
5,642,096
|
(5)
|
|
|
14.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Vinder
Sokhi
|
|
Director
and Chief Operating Officer
|
|
|
1,287,525
|
(6)
|
|
|
3.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Jim
Kilman
|
|
Director
|
|
|
1,529,632
|
(7)
|
|
|
3.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Page
Feldman
|
|
Director
|
|
|
102,500
|
|
|
|
0.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
All
directors and executive officers as a group (8 persons)
|
|
|
|
|
21,399,649
|
|
|
|
54.8
|
%
|
|
(1)
|
Includes
currently exercisable stock options to purchase 500,000 shares of our common stock, 129,632 shares of our common stock issuable
upon conversion of Series A Preferred stock, and currently exercisable warrants to purchase 100,000 shares of our common stock.
|
|
|
|
|
(2)
|
Includes
312,525 shares of our common stock issuable upon conversion of Series A Preferred stock and currently exercisable warrants
to purchase 250,000 shares of our common stock.
|
|
|
|
|
(3)
|
Includes
currently exercisable stock options to purchase 300,000 shares of our common stock.
|
|
|
|
|
(4)
|
Includes
currently exercisable stock options to purchase 500,000 shares of our common stock.
|
|
|
|
|
(5)
|
Includes
currently exercisable stock options to purchase 250,000 shares of our common stock, 129,632 shares of our common stock issuable
upon conversion of Series A Preferred stock, and currently exercisable warrants to purchase 100,000 shares of our common stock.
|
|
|
|
|
(6)
|
Includes
28,600 shares of our common stock issuable upon conversion of Series A Preferred stock and currently exercisable warrants
to purchase 175,000 shares of our common stock.
|
|
|
|
|
(7)
|
Includes
currently exercisable stock options to purchase 500,000 shares of our common stock, 129,632 shares of our common stock issuable
upon conversion of Series A Preferred stock, and currently exercisable warrants to purchase 600,000 shares of our common stock.
|
|
|
|
|
(8)
|
Includes
currently exercisable stock options to purchase 250,000 shares of our common stock.
|
Equity
Compensation Plan Information
The
following tables provides information as of December 31, 2018, with respect to shares of common stock that may be issued upon
exercise of outstanding stock options.
Equity
Compensation Plan Information as of December 31, 2018
Plan
category
|
|
Number
of shares of common stock to be issued upon exercise of outstanding options, warrants
and rights
(a)
|
|
|
Weighted-average
exercise
price
of outstanding options, warrants and rights
(b)
|
|
|
Number
of securities remaining available for future issuance under equity compensation plans
(excluding securities reflected in column (a))
(c)
|
|
Equity
compensation plans approved by security holders
|
|
|
15,724,000
|
|
|
$
|
1.60
|
|
|
|
9,276,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
compensation plans not approved by security holders
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
Total
|
|
|
15,724,000
|
|
|
$
|
1.60
|
|
|
|
9,276,000
|
|
ITEM
13.
|
Certain
Relationships and Related Transactions, and Director Independence
|
From
time to time, stockholders of the Company have advanced funds to us for working capital purposes. Those advances are unsecured,
non-interest bearing and due on demand. During the year ended December 31, 2018, we repaid $15,000 in advances to Jerome Feldman
and $7,000 to Steven Fludder, our former Chief Executive Office, and $250,000 was converted into preferred stock. As of December
31, 2018 and 2017, the outstanding amount of the advances from related parties was $36,000 and $308,000, respectively.
On
February 8, 2018, we entered into a preferred stock purchase agreement with several accredited and institutional investors, pursuant
to which the Company agreed to issue and sell in a private placement 1,950 shares of Series A Preferred Stock, as well as 975,000
warrants to purchase common stock at a purchase price of $1,000 per share, for total gross proceeds of $1.95 million. The warrants
have a 5-year term and an exercise price of $2.00. Jerome Feldman, our Executive Chairman and Treasures, invested $100,000, Stephen
Payne, Director, invested $100,000, Sam Pitroda, our Chief Executive Officer invested $500,000, and Jim Kilman, Director, invested
$100,000 through an affiliate.
On
May 17, 2017, we entered into a preferred stock purchase agreement with several accredited and institutional investors and issued
1,820 shares of Series A Preferred Stock and 910,000 warrants to purchase common stock, for total gross proceeds of $1.8 million
(including previous advances from related parties). The warrants have a 5-year term and an exercise price of $2.00. Jerome Feldman,
our Executive Chairman and Treasures, invested $100,000, Stephen Payne, a Director, invested $100,000, and Jim Kilman, a Director,
invested $100,000 through an affiliate.
Director
Independence
Our
Board of Directors has determined that each of Mr. Kilman and Mr. Payne would be considered an “independent director”.
Although we do not have any securities listed on the NASDAQ Stock Market, we have used its independence criteria in making this
determination in accordance with applicable SEC rules. Our other three current directors are not “independent” as
they are or recently were executive officers of our company.
ITEM
14.
|
Principal
Accountant Fees and Services
|
We
engaged EisnerAmper LLP as our independent registered public accounting firm for the fiscal years ending December 31, 2014, 2015,
2016, 2017 and 2018.
Audit
Fees
Audit
fees are those fees billed for professional services rendered for the audit of the annual financial statements. A total of $120,000
and $114,000 in audit fees were billed by EisnerAmper LLP for the years ended December 31, 2018 and 2017, respectively.
Audit-related
Fees
Audit-related
fees are fees billed for professional services other than the audit of our financial statements. For the years ended December
31, 2018 and 2017, no audit-related fees were billed by EisnerAmper LLP.
Tax
Fees
Tax
fees are those fees billed for professional services rendered for tax compliance, including preparation of corporate federal and
state income tax returns, tax advice and tax planning. For the years ended December 31, 2018 and 2017, no tax fees were billed
by EisnerAmper LLP.
All
Other Fees
No
other fees were billed by our independent registered public accounting firm in 2018 and 2017.
Audit
Committee
Mr.
Kilman and Mr. Payne serve as the members of our Audit Committee. Our Board of Directors approved the services rendered and fees
charged by our independent registered public accounting firm. Our Board of Directors has reviewed and discussed our audited financial
statements for the year ended December 31, 2018, with our management. In addition, our Board of Directors has discussed with EisnerAmper
LLP, our independent registered public accounting firm, the matters required to be discussed by the Public Accounting Oversight
Board’s (“PCAOB”) AS1301 (Communications with Audit Committee). Our Board of Directors also has received the
written disclosures as required by the Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees)
and our Board of Directors has discussed the independence of EisnerAmper LLP.
Based
on our Board of Directors’ review of the matters noted above and its discussions with our independent registered public
accounting firm and our management, our Board of Directors approved the audited financial statements included in this Form 10-K
for the year ended December 31, 2018.
Policy
for Pre-Approval of Audit and Non-Audit Services
Our
Board of Directors’ policy is to pre-approve all audit services and all non-audit services that our independent registered
public accounting firm is permitted to perform for us under applicable federal securities regulations. As permitted by the applicable
regulations, our Board of Directors’ policy utilizes a combination of specific pre-approval on a case-by-case basis of individual
engagements of the independent registered public accounting firm.
All
engagements of the independent registered public accounting firm to perform any audit services and non-audit services since the
date that EisnerAmper LLP was hired have been pre-approved by our Board of Directors in accordance with the pre-approval policy.
The policy has not been waived in any instance. All engagements of the independent registered public accounting firm to perform
any audit services and non-audit services prior to the date the pre-approval policy was implemented were approved by our Board
of Directors in accordance its normal functions.
ALPHA-EN
CORPORATION
CONSOLIDATED
BALANCE SHEETS
(in
thousands, except share and per share data)
|
|
December
31, 2018
|
|
|
December
31, 2017
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
518
|
|
|
$
|
562
|
|
Restricted
cash
|
|
|
15
|
|
|
|
15
|
|
Total
current assets
|
|
|
533
|
|
|
|
577
|
|
|
|
|
|
|
|
|
|
|
Long-term
deposit
|
|
|
35
|
|
|
|
35
|
|
Property
and equipment, net
|
|
|
632
|
|
|
|
501
|
|
Total
assets
|
|
$
|
1,200
|
|
|
$
|
1,113
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ DEFICIT AND TEMPORARY EQUITY
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
$
|
557
|
|
|
$
|
1,103
|
|
Advances
from related parties
|
|
|
36
|
|
|
|
308
|
|
Current
portion of deferred rent
|
|
|
10
|
|
|
|
-
|
|
Total
current liabilities
|
|
|
603
|
|
|
|
1,411
|
|
|
|
|
|
|
|
|
|
|
Deferred
rent
|
|
|
105
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities
|
|
|
708
|
|
|
|
1,411
|
|
|
|
|
|
|
|
|
|
|
Preferred
stock par value $0.01: 5,000,000 shares authorized; 4,208 shares and 1,935 shares issued and outstanding as of December 31,
2018 and December 31, 2017, respectively; aggregate liquidation preference of $4,208 and $1,935 as of December 31, 2018 and
December 31, 2017, respectively
|
|
|
4,208
|
|
|
|
1,935
|
|
|
|
|
|
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES (Note 9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
deficit:
|
|
|
|
|
|
|
|
|
Class
B common stock no par value: 1,000,000 shares authorized; none issued or outstanding
|
|
|
-
|
|
|
|
-
|
|
Common
stock par value $0.01: 57,000,000 shares authorized; 39,044,549 shares and 33,350,506 shares issued and 38,329,799 shares
and 32,635,756 shares outstanding at December 31, 2018 and December 31, 2017, respectively
|
|
|
390
|
|
|
|
334
|
|
Additional
paid-in capital
|
|
|
21,586
|
|
|
|
18,482
|
|
Treasury
stock at cost: 714,750 shares as of December 31, 2018 and December 31, 2017
|
|
|
(69
|
)
|
|
|
(69
|
)
|
Accumulated
deficit
|
|
|
(25,623
|
)
|
|
|
(20,276
|
)
|
Stockholders’
deficit attributed to alpha-En Corporation stockholders
|
|
|
(3,716
|
)
|
|
|
(1,529
|
)
|
Non-controlling
interest
|
|
|
-
|
|
|
|
(704
|
)
|
Total
stockholders’ deficit
|
|
|
(3,716
|
)
|
|
|
(2,233
|
)
|
TOTAL
LIABILITIES AND STOCKHOLDERS’ DEFICIT AND TEMPORARY EQUITY
|
|
$
|
1,200
|
|
|
$
|
1,113
|
|
See
accompanying notes to the consolidated financial statements.
ALPHA-EN
CORPORATION
CONSOLIDATED
STATEMENTS OF OPERATIONS
(in
thousands, except share and per share data)
|
|
For
the Years Ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
General
and administrative
|
|
$
|
4,225
|
|
|
$
|
4,367
|
|
Legal
and professional fees
|
|
|
501
|
|
|
|
537
|
|
Research
and development (includes stock based compensation of $(467) for the year ended December 31, 2018, and $1,418 for year ended
December 31, 2017, respectively. See Note 7)
|
|
|
773
|
|
|
|
1,927
|
|
Total
operating expenses
|
|
|
5,499
|
|
|
|
6,831
|
|
|
|
|
|
|
|
|
|
|
Other
income (loss)
|
|
|
|
|
|
|
|
|
Loss
on extinguishment of accounts payable
|
|
|
-
|
|
|
|
(82
|
)
|
Other
expenses
|
|
|
(5
|
)
|
|
|
-
|
|
Interest
income
|
|
|
2
|
|
|
|
2
|
|
Total
other loss
|
|
|
(3
|
)
|
|
|
(80
|
)
|
Net
loss
|
|
|
(5,502
|
)
|
|
|
(6,911
|
)
|
Less:
Net loss attributable to non-controlling interest
|
|
|
(155
|
)
|
|
|
(384
|
)
|
Net
loss attributable to controlling interest
|
|
|
(5,347
|
)
|
|
|
(6,527
|
)
|
Less:
Dividends accrued on preferred stock
|
|
|
(378
|
)
|
|
|
(115
|
)
|
Less:
Deemed dividend on Series A preferred stock
|
|
|
(687
|
)
|
|
|
(649
|
)
|
Less:
Deemed dividend - beneficial conversion feature on preferred stock
|
|
|
(956
|
)
|
|
|
(807
|
)
|
Net
loss attributable to alpha-En Corporation common stockholders
|
|
$
|
(7,368
|
)
|
|
$
|
(8,098
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss per share attributable to alpha-En Corporation common stockholders
|
|
|
|
|
|
|
|
|
Basic
and diluted
|
|
$
|
(0.20
|
)
|
|
$
|
(0.24
|
)
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
and diluted
|
|
|
36,538,284
|
|
|
|
33,312,970
|
|
See
accompanying notes to the consolidated financial statements.
ALPHA-EN
CORPORATION
CONSOLIDATED
STATEMENTS STATEMENT OF STOCKHOLDERS’ DEFICIT
(in
thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Common
Stock
|
|
|
Additional
Paid-In
|
|
|
Treasury
Stock
|
|
|
Accumulated
|
|
|
Noncontrolling
|
|
|
Stockholders’
Equity
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Shares
|
|
|
Amount
|
|
|
Deficit
|
|
|
Interest
|
|
|
(Deficit)
|
|
Balance
at December 31, 2016
|
|
|
33,282,089
|
|
|
$
|
333
|
|
|
$
|
13,987
|
|
|
|
714,750
|
|
|
$
|
(69
|
)
|
|
$
|
(13,749
|
)
|
|
$
|
(320
|
)
|
|
$
|
182
|
|
Stock
based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
4,189
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,189
|
|
Warrant
issued for services
|
|
|
-
|
|
|
|
-
|
|
|
|
249
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
249
|
|
Common
stock and warrants issued for extinguishment of accounts payable
|
|
|
62,417
|
|
|
|
1
|
|
|
|
191
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
192
|
|
Options
exercised for cash
|
|
|
6,000
|
|
|
|
-
|
|
|
|
6
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6
|
|
Issuance
of warrants to purchase common stock associated with preferred stock offering
|
|
|
-
|
|
|
|
-
|
|
|
|
649
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
649
|
|
Deemed
dividend on Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(649
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(649
|
)
|
Beneficial
conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
807
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
807
|
|
Deemed
dividends related to beneficial conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(807
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(807
|
)
|
Vested
options exchanged for cash
|
|
|
-
|
|
|
|
-
|
|
|
|
(25
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(25
|
)
|
Accrued
Series A dividends
|
|
|
-
|
|
|
|
-
|
|
|
|
(115
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(115
|
)
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(6,527
|
)
|
|
|
(384
|
)
|
|
|
(6,911
|
)
|
Balance
at December 31, 2017
|
|
|
33,350,506
|
|
|
$
|
334
|
|
|
$
|
18,482
|
|
|
|
714,750
|
|
|
$
|
(69
|
)
|
|
$
|
(20,276
|
)
|
|
$
|
(704
|
)
|
|
$
|
(2,233
|
)
|
Stock
based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
2,280
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,280
|
|
Shares
issued for acquiring ownership of subsidiary
|
|
|
3,018,150
|
|
|
|
30
|
|
|
|
(889
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
859
|
|
|
|
-
|
|
Warrant
issued for services
|
|
|
-
|
|
|
|
-
|
|
|
|
40
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
40
|
|
Issuance
of common stock for cash in private placements
|
|
|
1,534,433
|
|
|
|
15
|
|
|
|
1,785
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,800
|
|
Preferred
stock converted to common stock
|
|
|
31,460
|
|
|
|
-
|
|
|
|
55
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
55
|
|
Options
exercised for cash
|
|
|
110,000
|
|
|
|
1
|
|
|
|
21
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
22
|
|
Warrants
exercised for cash
|
|
|
1,000,000
|
|
|
|
10
|
|
|
|
190
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
200
|
|
Issuance
of warrants to purchase common stock associated with preferred stock offering
|
|
|
-
|
|
|
|
-
|
|
|
|
687
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
687
|
|
Deemed
dividend on Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(687
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(687
|
)
|
Beneficial
conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
956
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
956
|
|
Deemed
dividends related to beneficial conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(956
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(956
|
)
|
Accrued
Series A dividends
|
|
|
-
|
|
|
|
-
|
|
|
|
(378
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(378
|
)
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,347
|
)
|
|
|
(155
|
)
|
|
|
(5,502
|
)
|
Balance
at December 31, 2018
|
|
|
39,044,549
|
|
|
$
|
390
|
|
|
$
|
21,586
|
|
|
|
714,750
|
|
|
$
|
(69
|
)
|
|
$
|
(25,623
|
)
|
|
$
|
-
|
|
|
$
|
(3,716
|
)
|
See
accompanying notes to the consolidated financial statements.
ALPHA-EN
CORPORATION
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(in
thousands)
|
|
For
the Years Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Cash
flows from operating activities
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(5,502
|
)
|
|
$
|
(6,911
|
)
|
|
|
|
|
|
|
|
|
|
Adjustments
to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
116
|
|
|
|
65
|
|
Stock-based
compensation
|
|
|
2,280
|
|
|
|
4,189
|
|
Warrant
issued for services
|
|
|
40
|
|
|
|
249
|
|
Loss
on extinguishment of accounts payable
|
|
|
-
|
|
|
|
82
|
|
Changes
in operating assets and liabilities of business, net of acquisitions:
|
|
|
|
|
|
|
|
|
Prepaid
expenses
|
|
|
-
|
|
|
|
91
|
|
Accounts
payable and accrued expenses
|
|
|
(605
|
)
|
|
|
249
|
|
Deferred
rent
|
|
|
115
|
|
|
|
-
|
|
Net
cash used in operating activities
|
|
|
(3,556
|
)
|
|
|
(1,986
|
)
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
|
|
|
|
|
Purchase
of fixed assets
|
|
|
(188
|
)
|
|
|
(25
|
)
|
Net
cash used in investing activities
|
|
|
(188
|
)
|
|
|
(25
|
)
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities
|
|
|
|
|
|
|
|
|
Proceeds
from issuance of preferred stock and warrants
|
|
|
1,700
|
|
|
|
1,670
|
|
Proceeds
from issuance of common stock in private placements
|
|
|
1,800
|
|
|
|
-
|
|
Options
exercised for cash
|
|
|
22
|
|
|
|
6
|
|
Vested
options exchanged for cash
|
|
|
-
|
|
|
|
(25
|
)
|
Warrants
exercised for cash
|
|
|
200
|
|
|
|
-
|
|
Advances
from related parties
|
|
|
-
|
|
|
|
412
|
|
Repayments
of advances from related parties
|
|
|
(22
|
)
|
|
|
(32
|
)
|
Net
cash provided by financing activities
|
|
|
3,700
|
|
|
|
2,031
|
|
|
|
|
|
|
|
|
|
|
Net
(decrease) increase in cash
|
|
|
(44
|
)
|
|
|
20
|
|
Cash
and restricted cash at beginning of period
|
|
|
612
|
|
|
|
592
|
|
Cash
and restricted cash at end of period
|
|
$
|
568
|
|
|
$
|
612
|
|
|
|
|
|
|
|
|
|
|
Non
cash financing and investing activities:
|
|
|
|
|
|
|
|
|
Beneficial
conversion feature of Series A preferred stock and deemed dividends related to beneficial conversion feature of Series A preferred
stock
|
|
$
|
(956
|
)
|
|
$
|
(807
|
)
|
Issuance
of warrants in preferred stock offering and deemed dividend on Series A preferred stock
|
|
$
|
(687
|
)
|
|
$
|
(649
|
)
|
Accrued
Series A dividends
|
|
$
|
(378
|
)
|
|
$
|
(115
|
)
|
Conversion
of advances from related parties to preferred stock
|
|
$
|
250
|
|
|
$
|
150
|
|
Common
stock and warrants issued for extinguishment of accounts payable
|
|
$
|
-
|
|
|
$
|
192
|
|
Preferred
stock converted to common stock
|
|
$
|
55
|
|
|
$
|
-
|
|
Purchase
of assets included in accounts payable
|
|
$
|
59
|
|
|
$
|
-
|
|
Forgiveness
of the lease payments
|
|
$
|
104
|
|
|
$
|
-
|
|
Shares
issued for acquiring ownership of subsidiary
|
|
$
|
30
|
|
|
$
|
-
|
|
See
accompanying notes to the consolidated financial statements.
Note
1 - Organization and Operations
alpha-En
Corporation (the “Company”) was incorporated in Delaware on March 7, 1997.
Since
2008, the focus of the Company’s business has been developing new technologies for manufacturing highly pure lithium metal,
a raw material for use in lightweight, high energy density batteries, in an environmentally friendly manner for commercial purposes.
In 2013, the Company invented a new process for the production of highly pure lithium metal and associated products at room temperature.
The Company subsequently broadened its focus to develop products and processes derived from the Company’s new core proprietary
technology, including battery components and compounds of lithium.
Ownership
of Subsidiary
In
September 2014, alpha-En Corporation formed Clean Lithium Corporation (“CLC”) under the laws of New York State as
a wholly owned subsidiary with a nominal share capital of $100,000. From 2014 to 2016, the Company sold 9.05% or 905,000 of CLC’s
shares to minority equity holders. Effective as of June 14, 2018, the Company completed the purchase of all of the outstanding
shares of CLC such that CLC became a wholly-owned subsidiary of the Company and was immediately thereafter merged with and into
the Company, with the Company surviving. In connection with this transaction, the former minority equity holders of CLC prior
to the merger received an aggregate total of 3,018,150 shares of common stock of the Company. The Company recorded the acquisition
of CLC as a capital transaction.
Note
2 - Going Concern and Liquidity
The
Company’s consolidated financial statements have been prepared assuming that it will continue as a going concern, which
contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.
As
reflected in the consolidated financial statements, the Company had an accumulated deficit of approximately $25.6 million and
a negative working capital of $70,000 at December 31, 2018. For the years ending December 31, 2018 and 2017, the Company
had a net loss of approximately $5.5 million and $6.9 million, and net cash used in operating activities of approximately $3.6
million and $2.0 million, respectively. These factors raise substantial doubt about the Company’s ability to continue as
a going concern.
The
Company is attempting to further develop the intellectual property associated with its technology; broaden its patent portfolio;
scale up its production of various products; and begin generating revenue; however, the Company’s cash position is not sufficient
to support its daily operations for the foreseeable future. While the Company believes in the viability of its technology and
in its ability to raise additional funds by way of a public or private offering, there can be no assurances to that effect. The
ability of the Company to continue as a going concern is dependent upon its ability to raise additional funds by way of a public
or private offering and its ability to further develop its technology and generate sufficient revenue.
The
consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue
as a going concern.
Note
3 - Significant and Critical Accounting Policies and Practices
Basis
of Presentation and Principles of Consolidation
On
June 14, 2018, the Company completed the purchase all of the outstanding shares of CLC such that CLC became a wholly-owned subsidiary
of the Company and was immediately thereafter merged with and into the Company, with the Company surviving. Accordingly, as of
June 14, 2018, the Company no longer has any subsidiaries consolidated in these financial statements.
For
the year ended December 31, 2017 and through June 14, 2018, the accompanying consolidated financial statements include the accounts
of the Company’s subsidiary. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company
records net loss attributable to non-controlling interests in its statements of operations equal to the percentage of the economic
or ownership interest retained in such entities by the respective non-controlling parties. All intercompany accounts and transactions
have been eliminated in consolidation.
Use
of Estimates
The
Company’s consolidated financial statements include certain amounts that are based on management’s best estimates
and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived
assets, fair value used in estimating the value of warrants, stock-based compensation, accrued expenses and provisions for income
taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair
Value Measurement
The
Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on
a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.
The
accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:
Level
1
:
|
Quoted
prices in active markets for identical assets or liabilities.
|
|
|
Level
2:
|
Observable
inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
|
|
|
Level
3:
|
Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined
using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination
of fair value requires significant judgment or estimation.
|
The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs
when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest
level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular
input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the
asset or liability. The Company also measures the fair value of certain assets on a non-recurring basis, generally on an annual
basis, or when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable.
The
carrying amounts of cash, accounts payable and accrued expenses and advances from related parties approximate fair value as these
accounts are largely current and short term in nature.
During
the years ended December 31, 2018 and 2017, we issued 78,000 and 250,000 warrants to a service provider, and the fair value of
the warrants were $40,000 and $249,000, respectively.
Cash
As
of December 31, 2018 and 2017, substantially all of the Company’s cash was held by major financial institutions and the
balance at certain times may exceed the maximum amount insured by the Federal Deposits Insurance Corporation. However, the Company
has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such
accounts.
Restricted
Cash
The
following is a summary of cash and restricted cash total as presented in the statements of cash flows for the years ended December
31, 2018 and 2017:
|
|
For
the Years Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Cash
|
|
$
|
518
|
|
|
$
|
562
|
|
Restricted
cash
|
|
|
15
|
|
|
|
15
|
|
Long-term
deposit
|
|
|
35
|
|
|
|
35
|
|
Total
cash and restricted cash
|
|
$
|
568
|
|
|
$
|
612
|
|
Property
and Equipment
Lab
equipment and office equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life
of each asset, generally three to eight years. Leasehold improvements are amortized over the shorter of the estimated useful lives
or the term of the respective leases.
Impairment
of Long-Lived Assets
The
Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when
to perform an impairment review include significant underperformance of the business in relation to expectations, significant
negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review
is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected
to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized
when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The
impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. There were no indicators
of impairment for long-lived assets during the years ended December 31, 2018 and 2017.
Fair
Value of Preferred Stock
The
fair value of Preferred stock was estimated based upon equivalent common shares that Preferred Stock could have been converted
into at the closing price on the purchase date.
Convertible
Financial Instruments
The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial
instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks
of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host
contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured
at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings
as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative
instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under
applicable GAAP.
When
the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts
are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the
fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded
in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares
based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and
the effective conversion price embedded in the preferred shares.
Research
and Development
Research
and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and
development activities are expensed when the activity has been performed or when the goods have been received rather than when
the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the
Company’s behalf will be expensed as services are rendered or when the milestone is achieved.
Research
and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related
expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products
and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing
research trial materials, and costs associated with regulatory filings, laboratory costs and other supplies.
In
accordance with ASC 730-10-25-1,
Research and Development
, costs incurred in obtaining technology licenses are charged
to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future
use. Certain licenses purchased by the Company require substantial completion of research and development and regulatory and marketing
approval efforts in order to reach commercial feasibility and have no alternative future use.
During
the year ended December 31, 2018, the Company commenced and scaled up the efforts at the Company’s Yonkers lab facility.
The Company also continued efforts at research universities and a national research lab for additional work related to development
and scale-up of the Company’s processes.
Contingencies
The
Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency
when it is probable that a liability has been incurred and the amount can be reasonably estimated.
If
a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based
Compensation
The
Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair
value of the awards. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee
awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value
of these non-employee awards are recognized as compensation expense in the period of change.
The
Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used
in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties
and the application of management’s judgment. The company accounts for forfeitures as incurred.
Income
Taxes
The
Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for
the future tax effects attributable to temporary differences between the consolidated financial statement carrying amounts of
existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company
establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an
evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the
Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that
are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.
Loss
Per Share
Basic
loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number
of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options,
unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive.
Securities
that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share
at December 31, 2018 and 2017 are as follows:
|
|
As
of December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Warrants
to purchase common stock
|
|
|
4,797,292
|
|
|
|
4,744,292
|
|
Options
to purchase common stock
|
|
|
15,724,000
|
|
|
|
8,874,000
|
|
Preferred
stock convertible into common stock
|
|
|
2,406,976
|
|
|
|
1,106,807
|
|
Total
|
|
|
22,928,268
|
|
|
|
14,725,099
|
|
Non-Controlling
Interests
Non-controlling
interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change
in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between
the controlling and non-controlling interests.
Recent
Accounting Pronouncements
The
Company considers the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not discussed below
were assessed and determined to be either not applicable or are expected to have minimal impact on the consolidated balance sheets
or statements of operations.
In
August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13,
Fair Value Measurement (Topic
820), – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement,
which makes
a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy
associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the update.
The Company is still evaluating but does not expect the adoption of this guidance to have a material impact on its Consolidated
Financial Statements.
In
August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,
Disclosure Update and Simplification
, amending
certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments
expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the
amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided
in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of
each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5,
2018. The Company plans to adopt this change in Q1 2019.
In
June 2018, the FASB issued ASU 2018-07,
Improvements to Nonemployee Share-Based Payment Accounting
, which simplifies the
accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such
payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take
effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year.
For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within
fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date
of Topic 606. The Company will adopt it on January 1, 2019 and expects the adoption of this pronouncement will eliminate significant
fluctuation in stock based compensation expensed in the past due to awards to non-employees.
In
August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments
,
which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain
cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal
years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the standard
as of January 1, 2018 and
adoption had a $150,000 impact of
restricted cash and long-term deposit on the cash and restricted cash balance at beginning of period.
In
February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842)
in order to increase transparency and comparability among
organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases
classified as operating leases under previous GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning
after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption
is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to
all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence
of a lease, (b) lease classification or (c) determination of initial direct costs, as of the adoption date, which effectively
allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases
(Topic 842): Targeted Improvements, which provides entities an optional transition method to apply the guidance under Topic 842
as of the adoption date, rather than as of the earliest period presented. The Company adopted Topic 842 on January 1, 2019, using
the optional transition method to apply the new guidance as of January 1, 2019, rather than as of the earliest period presented,
and elected the package of practical expedients described above. The Company is still finalizing its analysis, but expects to
recognize additional operating liabilities of $1.1 million, with corresponding ROU assets of approximately the same amount as
of January 1, 2019 based on the present value of the remaining lease payments.
Note
4 - Property and Equipment
The
components of property and equipment as of December 31, 2018 and 2017, at cost are (dollars in thousands):
|
|
Useful
Life (Years)
|
|
|
December
31, 2018
|
|
|
December
31, 2017
|
|
Lab
equipment
|
|
|
3
|
|
|
$
|
415
|
|
|
$
|
173
|
|
Office
furniture and equipment
|
|
|
3
|
|
|
|
31
|
|
|
|
31
|
|
Leasehold
improvement
|
|
|
7
|
|
|
|
379
|
|
|
|
374
|
|
Gross
property and equipment
|
|
|
|
|
|
|
825
|
|
|
|
578
|
|
Less:
Accumulated depreciation and amortization
|
|
|
|
|
|
|
(193
|
)
|
|
|
(77
|
)
|
Property
and equipment, net
|
|
|
|
|
|
$
|
632
|
|
|
$
|
501
|
|
The
Company’s depreciation expense for the years ended December 31, 2018 and 2017 was $116,000 and $65,000, respectively.
Note
5 - Related Party Transactions
Advances
from Related Parties
From
time to time, stockholders of the Company advance funds to the Company for working capital purposes. Those advances are unsecured,
non-interest bearing and due on demand.
As
of December 31, 2018 and December 31, 2017, the outstanding amounts of the advances from related parties was approximately $36,000
and $308,000, respectively. For the year ended December 31, 2018, the Company repaid $15,000 in advances to Jerome Feldman and
$7,000 to Steven Fludder, our former Chief Executive Office, and $250,000 was converted into preferred stock. See Note 6 for more
details on advances converted to preferred stock.
Appointment
of Chief Financial Officer
On
February 23, 2017, the Board of Directors of the Company appointed Nathan Wasserman to become Chief Financial Officer of the Company,
effective as of March 1, 2017. Pursuant to a term sheet dated February 27, 2017, Mr. Wasserman agreed to serve as the Company’s
Chief Financial Officer for an initial term of three years. The Company granted Mr. Wasserman stock options to purchase a total
of 500,000 shares of common stock at an exercise price of $1.10 per share, of which 150,000 vested immediately, 150,000 vested
in his second year of service and 200,000 will vest in his third year of service. Mr. Wasserman receives salary of $5,000 per
month.
Appointment
of Chief Executive Officer
On
November 11, 2017, the Company appointed Sam Pitroda to serve as the Company’s new Chief Executive Officer. Since that time,
Mr. Pitroda has served as CEO without an employment agreement. The Company and Mr. Pitroda are in discussions to finalize the
terms of the employment agreement, although there can be no assurances that an agreement will be reached. On May 31, 2018, the
board of directors approved to grant Mr. Pitroda an option to purchase 7,000,000 shares of the Company’s common stock at
an exercise price of $2.08 per share. The option expires seven years from the option grant date. The stock subject to the option
will vest upon the earlier to occur of (1) the five-year anniversary of the option grant date or (2) the achievement of certain
stock price and volume milestones, which are as follows:
Common
stock price
closes
at or above
|
|
|
For
20 consecutive business
days,
with average daily
volumn
in excess of
|
|
|
Total
option shares that
become
vested on satisfaction
of
conditions
|
$
|
3.00
|
|
|
|
20,000
|
|
|
2,000,000
(28.5%)
|
$
|
6.00
|
|
|
|
40,000
|
|
|
4,000,000
(51.7%)
|
$
|
11.00
|
|
|
|
60,000
|
|
|
7,000,000
(100.0%)
|
The
total fair value of this option award on the grant date was approximately $7.6 million. The fair value of the option award was
determined using the Black-Scholes model with the following assumptions: risk free interest rate – 2.7%, volatility –
78.0%, expected term – 4 years and dividends– N/A. The Company will amortize the option over its service period of
4.09 years which was derived from a Monte Carlo simulation. Stock-based compensation expense for this option recognized for the
year ended December 31, 2018 was $1.1 million.
On
February 8, 2018, Sam Pitroda through Pitroda Group LLC invested $500,000 and the Company issued 500 Series A Preferred Stock
and 250,000 warrants to purchase the Company’s common stock. The warrants have a 5-year term and an exercise price of $2.00.
On
September 1 2017, Steven Fludder, former CEO, resigned from the Company. On June 22, 2018, the Company vested 150,000 stock options
that would have been forfeited. The Company recorded additional stock compensation expense of $234,000 related to this stock option
modification.
Note
6 - Temporary Equity
Series
A Preferred Stock
The
following table summarizes the Company’s Series A Preferred Stock activities for the year ended December 31, 2018 (dollars
in thousands):
|
|
Series
A Preferred Stock
|
|
|
|
Shares
|
|
|
Amount
|
|
Total
temporary equity as of December 31, 2017
|
|
|
1,935
|
|
|
$
|
1,935
|
|
Sale
of Series A preferred stock
|
|
|
1,700
|
|
|
|
1,700
|
|
Conversion
of advances into preferred stock
|
|
|
250
|
|
|
|
250
|
|
Preferred
stock converted to common stock
|
|
|
(55
|
)
|
|
|
(55
|
)
|
Beneficial
conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
(956
|
)
|
Deemed
dividends related to beneficial conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
956
|
|
Accrued
Series A dividends
|
|
|
378
|
|
|
|
378
|
|
Deemed
dividend on Series A preferred stock
|
|
|
-
|
|
|
|
687
|
|
Fair
Value of common stock warrant issued with Series A preferred stock
|
|
|
-
|
|
|
|
(687
|
)
|
Total
temporary equity as of December 31, 2018
|
|
|
4,208
|
|
|
$
|
4,208
|
|
The
following table summarizes the Company’s Series A Preferred Stock activities for the year ended December 31, 2017 (dollars
in thousands):
|
|
Series
A Preferred Stock
|
|
|
|
Shares
|
|
|
Amount
|
|
Total temporary
equity as of December 31, 2016
|
|
|
-
|
|
|
$
|
-
|
|
Proceeds
from sale of Series A preferred stock
|
|
|
1,670
|
|
|
|
1,670
|
|
Conversion
of advances into preferred stock
|
|
|
150
|
|
|
|
150
|
|
Beneficial
conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
(807
|
)
|
Deemed
dividends related to beneficial conversion feature of Series A preferred stock
|
|
|
-
|
|
|
|
807
|
|
Accrued
Series A dividends
|
|
|
115
|
|
|
|
115
|
|
Deemed
dividend on Series A preferred stock
|
|
|
-
|
|
|
|
649
|
|
Fair
Value of common stock warrant issued with Series A preferred stock
|
|
|
-
|
|
|
|
(649
|
)
|
Total
temporary equity as of December 31, 2017
|
|
|
1,935
|
|
|
$
|
1,935
|
|
On
February 8, 2018, the Company entered into a preferred stock purchase agreement (“Stock Purchase Agreement”) with
several accredited and institutional investors, pursuant to which the Company agreed to issue and sell in a private placement
1,950 shares of Series A Preferred Stock, as well as 975,000 warrants to purchase the Company’s common stock, at a purchase
price of $1,000 per share, for total gross proceeds of $1.95 million (including previous advances from related parties). The warrants
have a 5-year term and an exercise price of $2.00. Steven M. Payne converted $100,000, Jerome I. Feldman converted $50,000 and
Jim Kilman through KielStrand Capital LLC converted $100,000 advances into preferred stock. Sam Pitroda through Pitroda Group
LLC invested $500,000 and the Company issued 500 Series A Preferred Stock and 250,000 warrants, which included in the total Preferred
Stock and warrant count described above, on the same terms as other accredited and institutional investors.
The
Company has determined that the warrants should be accounted as a component of stockholders’ equity. On the issuance date,
the Company estimated the fair value of the warrants at $1.2 million using the Black-Scholes option pricing model using the following
primary assumptions: contractual term of 5.0 years, volatility rate of 74.8%, risk-free interest rate of 2.57% and expected dividend
rate of 0%. Based on the warrant’s relative fair value to the fair value of the Series A Preferred, approximately $687,000
of the $1.2 million of aggregate fair value was allocated to the warrants, creating a corresponding preferred stock discount in
the same amount.
Due
to the reduction of allocated proceeds to Series A Preferred, the effective conversion price was approximately $1.13 per share
creating a beneficial conversion feature of $956,000 which further reduced the carrying value of the Series A Preferred. Since
the conversion option of the Series A Preferred was immediately exercisable, the discounts resulting from the warrants and the
beneficial conversion feature were immediately accreted to preferred dividends, resulting in an increase in the carrying value
of the Series A Preferred.
On
May 17, 2017, the Company entered into a preferred stock purchase agreement (“Stock Purchase Agreement”) with several
accredited and institutional investors, pursuant to which the Company agreed to issue and sell in a private placement 1,820 shares
of its newly designated Series A Preferred Stock, par value $0.01 per share (“Series A Preferred”), as well as 910,000
warrants to purchase the Company’s common stock, par value $0.01 per share (“Common Stock”), at a purchase price
of $1,000 per share, for total gross proceeds of $1.82 million (including previous advances from related parties). The warrants
have a 5-year term and an exercise price of $2.00. Steven M. Payne, Jerome I. Feldman and Jim Kilman each converted $50,000 advances
into preferred stock.
The
Company has determined that the warrants should be accounted as a component of stockholders’ equity. On the issuance date,
the Company estimated the fair value of the warrants at $1.1 million using the Black-Scholes option pricing model using the following
primary assumptions: contractual term of 5.0 years, volatility rate of 79.8%, risk-free interest rate of 1.76% and expected dividend
rate of 0%. Based on the warrant’s relative fair value to the fair value of the Series A Preferred, approximately $649,000
of the $1.1 million of aggregate fair value was allocated to the warrants, creating a corresponding preferred stock discount in
the same amount.
Due
to the reduction of allocated proceeds to Series A Preferred, the effective conversion price was approximately $1.1 per share
creating a beneficial conversion feature of $807,000. Since the conversion option of the Series A Preferred was immediately exercisable,
the discounts resulting from the warrants and the beneficial conversion feature were immediately accreted to preferred dividends,
resulting in an increase in the carrying value of the Series A Preferred.
During
the year ended December 31, 2018, there were 55 shares of preferred stock converted into 31,460 shares of common stock. As of
December 31, 2018 and 2017, the dividends accrued and outstanding were $378,000 and $115,000, respectively, and reflected in carrying
value of temporary equity.
The
Series A Preferred is entitled to accrue cumulative dividends at a rate equal to 10.0% simple interest per annum on the original
issue price of $1,000 per share (the “Original Issue Price”). Accrued dividends will be payable quarterly based on
a 365-day year and may be paid in cash or in additional shares of Series A Preferred. Each share of Series A Preferred is convertible
into 572 shares of Common Stock, subject to customary increases or decreases for stock splits, stock dividends recapitalizations
and the like, and may be converted to Common Stock at any time after issuance at the option of a holder. The Company will have
the right, at the Company’s option, to redeem all or a portion of the shares of Series A Preferred Stock at any time or
times after the one year anniversary of the Issuance Date of such Series A Preferred Stock, at a price per share (the “Redemption
Price”) equal to the sum of the following (without duplication): (a) the Original Issue Price, plus (b) any accrued but
unpaid Dividends. Upon any liquidation, dissolution or winding up of the Company, liquidation of the Company’s assets will
be made in the following order of priority: (a) first, payment or provision for payment of debts and other liabilities; (b) second,
payment to the holders of Series A Preferred an amount with respect to each share of Series A Preferred equal to the Original
Issue Price, plus any accrued but unpaid Dividends thereon; and (c) third, payment to the holders of Common Stock. Except as required
by applicable law or as set forth herein, the holders of shares of Series A Preferred Stock will vote together with the holders
of shares of Common Stock and not as a separate class. Each share of Series A Preferred Stock will have a number of votes equal
to the number of shares of Common Stock then issuable upon conversion of such share of Series A Preferred Stock.
The
Series A Preferred Stock is being classified as temporary equity because it has redemption features that are outside of the Company’s
control upon certain triggering events, such as a deemed liquidation event. A “Deemed Liquidation Event” is defined
in the Company’s Amended and Restated Certificate of Incorporation as a merger that results in a change in control or the
sale of substantially all the assets of the Company. In the case of a Deemed Liquidation Event, the assets of the Company will
be paid in order of liquidation preference to the holders of preferred and common stock. Because certain holders of the Series
A Preferred Stock constitute a majority of the Company’s Board of Directors, a potential Deemed Liquidation Event is considered
to be outside the control of the Company along with the call provision that can be exercised in one year, resulting in classification
of the Series A Preferred Stock as temporary equity.
Note
7 - Stockholders’ Equity
Common
Stock
On
March 21, 2018, the Company entered into a private placement offering with an investor and issued 826,446 shares of its common
stock for $1.0 million. In addition, the Company granted this investor the non-exclusive rights to distribute its product in China
for a period of two years. In connection with this private placement, the Company issued 41,322 shares of common stock to an investor
as a finder’s fee.
On
August 23, 2018, the Company entered into a private placement offering with three investors and issued 666,665 shares of its common
stock for $800,000.
Stock
Options
The
fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of
the awards was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend
yield is 0%. The expected term for stock options granted with service conditions represents the average period the stock options
are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by the Securities
and Exchange Commission’s Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock
options granted with performance and/or market conditions represents the period estimated by management by which the performance
conditions will be met. The Company obtained the risk-free interest rate from publicly available data published by the Federal
Reserve. The Company uses a methodology in estimating its volatility percentage from a computation that was based on a comparison
of average volatility rates of similar companies to a computation based on the standard deviation of the Company’s own underlying
stock price’s daily logarithmic returns. The grant date fair value of stock options granted to employees during years ended
December 31, 2018 and 2017 was $8.2 million and $4.3 million, respectively. The fair value of options granted during the years
ended December 31, 2018 and 2017 were estimated using the following weighted-average assumptions:
|
|
For
the Years Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Exercise
price
|
|
$
|
2.05
|
|
|
$
|
1.85
|
|
Expected
stock price volatility
|
|
|
78
|
%
|
|
|
79
|
%
|
Risk-free
rate of interest
|
|
|
2.68
|
%
|
|
|
1.61
|
%
|
Term
(years)
|
|
|
4.0
|
|
|
|
3.1
|
|
A
summary of option activity under the Company’s employee stock option plan for years ended December 31, 2018 and 2017 are
presented below:
|
|
Number
of Shares
|
|
|
Weighted Average
Exercise Price
|
|
|
Total Intrinsic
Value
|
|
|
Weighted Average
Remaining Contractual
Life (in years)
|
|
Outstanding
as of December 31, 2016
|
|
|
1,575,000
|
|
|
$
|
0.50
|
|
|
$
|
1,264,000
|
|
|
|
4.7
|
|
Employee
options granted
|
|
|
4,150,000
|
|
|
|
1.85
|
|
|
|
4,160,000
|
|
|
|
4.5
|
|
Exercised
|
|
|
(6,000
|
)
|
|
|
1.08
|
|
|
|
11,000
|
|
|
|
-
|
|
Forfeited
|
|
|
(50,000
|
)
|
|
|
1.85
|
|
|
|
6,000
|
|
|
|
-
|
|
Outstanding
as of December 31, 2017
|
|
|
5,669,000
|
|
|
|
1.48
|
|
|
|
7,793,000
|
|
|
|
4.3
|
|
Employee
options granted
|
|
|
7,610,000
|
|
|
|
2.06
|
|
|
|
-
|
|
|
|
6.3
|
|
Exercised
|
|
|
(100,000
|
)
|
|
|
0.20
|
|
|
|
152,000
|
|
|
|
-
|
|
Expired
|
|
|
(250,000
|
)
|
|
|
0.10
|
|
|
|
443,000
|
|
|
|
-
|
|
Forfeited
|
|
|
(300,000
|
)
|
|
|
1.25
|
|
|
|
-
|
|
|
|
-
|
|
Outstanding
as of December 31, 2018
|
|
|
12,629,000
|
|
|
$
|
1.87
|
|
|
$
|
357,000
|
|
|
|
5.2
|
|
Options
vested and expected to vest as of December 31, 2018
|
|
|
12,629,000
|
|
|
$
|
1.87
|
|
|
$
|
357,000
|
|
|
|
5.2
|
|
Options vested
and exercisable as of December 31, 2018
|
|
|
3,654,000
|
|
|
$
|
1.50
|
|
|
$
|
357,000
|
|
|
|
3.6
|
|
A
summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2018 and 2017 are
presented below:
|
|
Number
of Shares
|
|
|
Weighted Average
Exercise Price
|
|
|
Total
Intrinsic Value
|
|
|
Weighted
Average
Remaining Contractual
Life (in years)
|
|
Outstanding
as of December 31, 2016
|
|
|
2,955,000
|
|
|
$
|
0.27
|
|
|
$
|
3,053,000
|
|
|
|
3.2
|
|
Non-employee
options granted
|
|
|
250,000
|
|
|
|
1.95
|
|
|
|
225,000
|
|
|
|
4.6
|
|
Outstanding
as of December 31, 2017
|
|
|
3,205,000
|
|
|
|
0.40
|
|
|
|
7,847,000
|
|
|
|
2.4
|
|
Non-employee
options granted
|
|
|
200,000
|
|
|
|
1.64
|
|
|
|
-
|
|
|
|
3.7
|
|
Exercised
|
|
|
(10,000
|
)
|
|
|
0.20
|
|
|
|
22,000
|
|
|
|
-
|
|
Expired
|
|
|
(300,000
|
)
|
|
|
0.15
|
|
|
|
491,000
|
|
|
|
-
|
|
Outstanding
as of December 31, 2018
|
|
|
3,095,000
|
|
|
$
|
0.51
|
|
|
$
|
1,567,000
|
|
|
|
1.7
|
|
Options
vested and expected to vest as of December 31, 2018
|
|
|
3,095,000
|
|
|
$
|
0.51
|
|
|
$
|
1,567,000
|
|
|
|
1.7
|
|
Options vested
and exercisable as of December 31, 2018
|
|
|
2,645,000
|
|
|
$
|
0.51
|
|
|
$
|
1,339,000
|
|
|
|
1.7
|
|
Estimated
future stock-based compensation expense relating to unvested stock options are approximately $7.5 million and $2.1 million as
of December 31, 2018 and 2017, respectively, and will be amortized over the remaining 3.8 years and 2.8 years. Weighted average
remaining contractual life of the options is 4.5 years.
Warrants
A
summary of the status of the Company’s outstanding warrants as of December 31, 2018 and 2017 and changes during the year
then ended are presented below:
|
|
Number
of Warrants
|
|
|
Weighted Average
Exercise Price
|
|
|
Total
Intrinsic Value
|
|
|
Weighted
Average Remaining Contractual
Life (in years)
|
|
Outstanding
as of December 31, 2016
|
|
|
3,271,875
|
|
|
$
|
1.02
|
|
|
$
|
2,000,000
|
|
|
|
3.9
|
|
Issued
|
|
|
1,472,417
|
|
|
|
1.72
|
|
|
|
1,666,000
|
|
|
|
5.0
|
|
Outstanding
as of December 31, 2017
|
|
|
4,744,292
|
|
|
$
|
1.24
|
|
|
$
|
7,884,000
|
|
|
|
3.6
|
|
Issued
|
|
|
1,053,000
|
|
|
|
1.98
|
|
|
|
-
|
|
|
|
4.2
|
|
Exercised
|
|
|
(1,000,000
|
)
|
|
|
0.20
|
|
|
|
1,680,000
|
|
|
|
-
|
|
Outstanding
as of December 31, 2018
|
|
|
4,797,292
|
|
|
$
|
1.62
|
|
|
$
|
340,000
|
|
|
|
3.1
|
|
Warrants exercisable
as of December 31, 2018
|
|
|
4,547,292
|
|
|
$
|
1.64
|
|
|
$
|
340,000
|
|
|
|
3.0
|
|
During
the year ended December 31, 2018, the Company issued 975,000 warrants to purchase the Company’s common stock, with an exercise
price of $2.00, pursuant to a preferred stock purchase agreement with several accredited and institutional investors, and 78,000
warrants with an exercise price of $1.75 to a service provider. The 78,000 warrants were recorded as an advisory fee at a fair
value of $40,000. There were 1,000,000 warrants exercised for total proceeds of $200,000 for the year ended December 31, 2018.
During
the year ended December 31, 2017, the Company issued 910,000 warrants to purchase the Company’s common stock, with an exercise
price of $2.00, pursuant to a preferred stock purchase agreement with several accredited and institutional investors, and 62,417
warrants with a weighted-average exercise price of $1.76 to two service providers in payment of outstanding invoices. The Company
also granted 500,000 warrants with an exercise price of $1.20 to a service provider. 250,000 warrants were vested immediately;
the other 250,000 warrants will be vested upon performance of the service.
As
of December 31, 2018, weighted average remaining contractual life of the warrants is 3.0 years.
Stock-based
Compensation Expense
Stock-based
compensation expense for the years ended December 31, 2018 and 2017 was comprised of the following (in thousands):
|
|
For
the Year Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Employee
stock option awards
|
|
$
|
2,852
|
|
|
$
|
2,423
|
|
Non-employee
option awards
|
|
|
(572
|
)
|
|
|
1,766
|
|
Non-employee
warrants
|
|
|
40
|
|
|
|
249
|
|
Total
compensation expense
|
|
$
|
2,320
|
|
|
$
|
4,438
|
|
For
the year ended December 31, 2018, there were approximately $2.8 million stock-based compensation expense and $467,000 stock-based
compensation income included in the general and administrative and research and development expense, compared to $3.0 million
and $1.4 million stock-based compensation expenses included in the general and administrative and research and development expense
for the year ended December 31, 2017, respectively.
Note
8 - Extinguishment of Accounts Payable
During
year ended December 31, 2017, the Company issued 62,417 shares of common stock and 62,417 warrants to certain vendors in lieu
of $110,000 of outstanding accounts payable. The warrants have a 5-year term and a weighted-average exercise price of $1.76. The
fair value of common stock and warrant at the conversion date was approximately $110,000 and $82,000, respectively. The difference
of $82,000 was recorded as a loss on extinguishment of accounts payable.
Note
9 - Contingencies and Commitments
On
March 22, 2016, the Company entered into a lease (the “Lease”) with Hudson View Building #3, LLC (“the “Landlord”),
for office and laboratory space located in Yonkers, New York (the “Leased Premise”). The Leased Premise consists of
approximately 8,000 square feet. The Lease has a term of 87 months from the lease commencement date, which is the date upon which
the Landlord has substantially completed certain interior leasehold improvements to the Leased Premise. The annual rent of the
first year of the lease is approximately $208,000, increasing by 1.5% on each anniversary of the lease commencement date. In the
event of a termination of the lease following a default by us, the Company will be obligated to pay the sum of the rent payable
for the remainder of the lease term. the Company moved into the office on May 30, 2017. The Company began paying the monthly rent
during the quarter ended September 30, 2017. On March 31, 2018, the Company entered into a lease amendment agreement with the
Landlord, which resulted in abatement of rent for the period from October 2017 through March 2018, and the expiration date of
the Lease was extended to March 31, 2025. Therefore, the Company recorded approximately $115,000 deferred rent as of December
31, 2018, which will be amortized over the remaining lease period.
In
connection with this lease, the Company obtained an Irrevocable Standby Letter of Credit (the “Letter of Credit”)
from Chase Bank for a sum not exceeding $150,000. The Company have deposited this amount with Chase Bank as collateral for the
Letter of Credit and recorded the amount as restricted cash and long-term deposits in the balance sheets. During the year ended
December 31, 2017, $100,000 restricted cash was released to the Company.
As
of December 31, 2018, contractual minimal lease payments are as follows (in thousands):
2019
|
|
$
|
212
|
|
2020
|
|
|
215
|
|
2021
|
|
|
219
|
|
2022
|
|
|
222
|
|
2023
|
|
|
225
|
|
Thereafter
|
|
|
286
|
|
Total
|
|
$
|
1,379
|
|
Note
10 - Deferred Tax Assets and Income Tax Provision
The
Company had no income tax expense due to operating loss incurred for the years ended December 31, 2018 and 2017.
On
December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act
(the “Tax Act”), which makes broad and complex changes to the U.S. tax code. Certain of these changes may be applicable
to the Company, including but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent, creating
a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax (“AMT”), modifying
the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31,
2017, and changing the rules pertaining to the taxation of profits earned abroad. Changes in tax rates and tax laws are accounted
for in the period of enactment. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018. Consequently,
the Company recorded a decrease related to deferred tax assets of $1.4 million exclusive of the corresponding change in the valuation
allowance, for the years ended December 31, 2017. Due to the full valuation allowance on the deferred tax assets, there is no
net adjustment to deferred tax expense or benefit due to the reduction of the corporate tax rate.
The
tax effects of temporary differences and tax losses and credit carry forwards that give rise to significant portions of deferred
tax assets and liabilities at December 31, 2018 and 2017 are comprised of the following (dollars in thousands):
|
|
As
of December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Deferred
tax assets:
|
|
|
|
|
|
|
|
|
Net-operating
loss carryforward
|
|
$
|
2,811
|
|
|
$
|
1,523
|
|
Stock
based compensation
|
|
|
2,773
|
|
|
|
1,752
|
|
Other
|
|
|
38
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
Deferred Tax Assets
|
|
|
5,622
|
|
|
|
3,275
|
|
Valuation
allowance
|
|
|
(5,622
|
)
|
|
|
(3,275
|
)
|
Deferred
Tax Asset, Net of Allowance
|
|
$
|
-
|
|
|
$
|
-
|
|
The
Company has approximately $5.5 million of federal and $3.1 million of state tax Net Operating Losses (“NOLs”) as
of December 31, 2017 that will begin to expire in 2037. The 2018 federal NOL carryforwards of $3.0 million are subject to an
80% limitation on future taxable income and will not expire. The state net operating loss carryforwards of $2.0 million, if
not utilized, will expire in 2037.
Furthermore,
as a result of changes in the ownership of our common stock and changes in our business operations, our ability to use our federal
NOLs may be limited under Internal Revenue Code Section 382 and 383. State NOLs are subject to similar limitations in many cases.
As a result, our substantial NOLs may not have any value to us.
In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or
all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled
reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case
the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount
of the deferred tax assets at December 31, 2018. The valuation allowance increased by approximately $2.3 million and $1.0 million
for the years ended as of December 31, 2018 and 2017, respectively.
The
expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:
|
|
For
the years ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Statutory
Federal Income Tax Rate
|
|
|
(21.0
|
)%
|
|
|
(34.0
|
)%
|
State
and local taxes, net of Federal tax benefit
|
|
|
(11.7
|
)%
|
|
|
(5.8
|
)%
|
Federal
tax rate change
|
|
|
0.0
|
%
|
|
|
11.9
|
%
|
Stock
based compensation
|
|
|
0.3
|
%
|
|
|
3.0
|
%
|
Warrant
issued for services
|
|
|
0.2
|
%
|
|
|
1.4
|
%
|
Loss
on extinguishment of accounts payable
|
|
|
0.0
|
%
|
|
|
0.5
|
%
|
Deferred
tax rate change
|
|
|
(10.2
|
)%
|
|
|
0.0
|
%
|
Change
in Valuation Allowance
|
|
|
42.4
|
%
|
|
|
23.0
|
%
|
|
|
|
|
|
|
|
|
|
Income
Taxes Provision
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
The
Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2018.
The
Company is in the process of preparing historical federal and state tax returns. Therefore, the Company’s net operating
loss carryovers will not be available to offset future taxable income, if any, until the tax returns are filed.
Alpha En (CE) (USOTC:ALPE)
Graphique Historique de l'Action
De Mar 2025 à Avr 2025
Alpha En (CE) (USOTC:ALPE)
Graphique Historique de l'Action
De Avr 2024 à Avr 2025